Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70679 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Aafreen Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Oncology Unit, Dr. BRAIRCH, AIIMS, New Delhi, India. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Neoplastic Stem Cells. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Leukaemic stem cells (LSCs) are chemo‐resistant leukaemia‐initiating clones that drive refractoriness and relapse in acute myeloid leukaemia (AML). The study evaluated the prognostic significance of LSC burden in treatment naïve AML patients. LSCs were quantified using Next‐generation flow cytometry; patients were stratified into LSC neg/low and LSC high groups based on the median LSC percentage, and correlated with post‐induction morphological remission and measurable residual disease (MRD) status, and long‐term outcomes including relapse‐free survival (RFS), event‐free survival (EFS) and overall survival (OS). LSCs were detectable in 93.5% patients, with a median frequency of 0.386%. Patients with LSC neg/low (≤0.386%) had higher rates of complete remission (CR) ( p = 0.05) and MRD negativity ( p = 0.002). Lower LSC burden was associated with improved RFS, EFS and OS (all p < 0.05) suggesting the prognostic relevance of LSC quantitation in AML. In both Cluster of Differentiation 34 positve (CD34+) and CD34 negative (CD34−) AML, low LSC% was associated with superior survival outcomes ( p < 0.05). LSC burden is a strong, independent predictor of response and survival in AML, and its integration with European LeukemiaNet risk‐stratification and MRD assessment may enhance risk refinement and individualized therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory Oncology Unit, Dr. BRAIRCH, AIIMS, New Delhi, India.
- Clinical Research Unit, AIIMS, New Delhi, India.
- Department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India.
- Department of Paediatrics, AIIMS, New Delhi, India.
ORCID-Profile: Smeeta Gajendra, Sandeep Rai, Vivek Kumar Singh, Rachna Seth
Förderung
- Indian Council of Medical Research
Zitieren
APA
Khan, A., Gajendra, S., Rai, S., Thakral, D., Singh, V. K., Upadhyay, A. D., Bakhshi, S., Seth, R., Sahoo, R. K., & Gupta, R. (2026). Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70679
Vancouver
Khan A, Gajendra S, Rai S, Thakral D, Singh VK, Upadhyay AD, et al. Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia. British Journal of Haematology. 2026. doi:10.1111/bjh.70679
BibTeX
@article{Khan2026,
author = {Khan, Aafreen and Gajendra, Smeeta and Rai, Sandeep and Thakral, Deepshi and Singh, Vivek Kumar and Upadhyay, Ashish Datt and Bakhshi, Sameer and Seth, Rachna and Sahoo, Ranjit Kumar and Gupta, Ritu},
title = {Leukaemic stem cell burden enhances prognostic precision in the non‐adverse European LeukemiaNet risk group of acute myeloid leukaemia},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70679}
}
EUVIMED